Castle Biosciences announces new data on DecisionDx-Melanoma test

Castle Biosciences (CSTL) announced new data demonstrating the clinical value of its DecisionDx-Melanoma test in improving sentinel lymph node biopsy decision making and enhancing recurrence risk prediction in patients with cutaneous melanoma. The data will be featured in two oral presentations at the 2nd European Congress on Dermato-Oncology, taking place Nov. 17-18, 2025, in Paris, France. SLNB helps stage patients with CM by determining whether cancer cells have spread beyond the primary tumor site, information that can help guide prognosis and treatment decisions. Current guidelines recommend considering SLNB when the estimated probability of a positive node exceeds 5%. Traditionally, that estimate is driven primarily by Breslow thickness and ulceration, which are key pathologic components used in staging. However, up to 88% of SLNB procedures yield negative results, and as many as 16% of SLN-negative patients still experience disease recurrence within five years, underscoring the need for tools that better identify who is likely to have a positive node and who may remain at risk despite a negative result.